Long-term use of ozanimod in patients with moderately to severely active ulcerative colitis

被引：0
|
作者：
Danese, S. [1 ]
Colombel, J-F [2 ]
Ponich, T. [9 ]
Jovanovic, I. [10 ]
Bossuyt, P. [11 ]
Longman, R. [3 ]
Alekseeva, O. [12 ]
Petersen, A. K. [4 ]
Marta, C. [4 ]
Charles, L. [4 ]
Sparrow, M. [13 ]
Rubin, D. T. [5 ]
Afzali, A. [6 ]
Loftus, E. V., Jr. [7 ]
Wolf, D. C. [8 ]
机构：
[1] IRCCS San Raffaele Hosp, Milan, Italy
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Weill Cornell Med, Jill Roberts Ctr Inflammatory Bowel Dis, New York, NY USA
[4] Bristol Myers Squibb, Princeton, NJ USA
[5] Univ Chicago, Med Inflammatory Bowel Dis Ctr, Chicago, IL USA
[6] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA
[7] Mayo Clin, Div Gastroenterol & Hepatol, Coll Med, Rochester, MN USA
[8] Atlanta Gastroenterol Assoc, Ctr Crohns Dis & Ulcerat Colitis, Atlanta, GA USA
[9] Western Univ, London, ON, Canada
[10] Univ Hosp Med Ctr Bezanijska Kosa, Div Gastroenterol, Belgrade, Serbia
[11] Imelda Gen Hosp, Imelda GI Clin Res Ctr, Bonheiden, Belgium
[12] Nizhny Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia
[13] Monash Univ, Alfred Hosp, Melbourne, Vic, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2022年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
89
引用
收藏
页码：125 / 126
页数：2
相关论文
共 50 条
  • [21] Guselkumab for moderately to severely active ulcerative colitis
    不详
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (02): : 112 - 112
  • [22] Filgotinib for moderately to severely active ulcerative colitis
    Mannucci, Alessandro
    D'Amico, Ferdinando
    El Saadi, Ahmad
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (10) : 927 - 940
  • [23] Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
    Millie, Long
    Raymond, Cross
    Jonathan, Calkwood
    Marc, Pondel
    Ashwini, Pai
    Harris, Ahmad
    Lorna, Charles
    Ayanbola, Elegbe
    AnnKatrin, Petersen
    James, Sheffield
    Adil, Javed
    Douglas, Wolf
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S9 - S10
  • [24] THE EFFECT OF OZANIMOD ON CIRCULATING NEUTROPHILS: RESULTS FROM THE TRUE NORTH STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Harris, Sarah
    Wu, Chun
    Li, Yicong
    Maddux, Rachel
    Hu, Sarah
    Petersen, AnnKatrin
    GASTROENTEROLOGY, 2022, 162 (07) : S973 - S973
  • [25] Mirikizumab in moderately to severely active ulcerative colitis: a profile of its use
    Fung, Simon
    Blair, Hannah A.
    DRUGS & THERAPY PERSPECTIVES, 2024, : 433 - 443
  • [26] SAFETY OF LONG-TERM OZANIMOD TREATMENT FOR UP TO 4 YEARS BY AGE GROUP IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
    Siegel, Corey A.
    Rubin, David T.
    Long, Millie D.
    Danese, Silvio
    Cross, Raymond K.
    Armuzzi, Alessandro
    Dignass, Axel
    Kobayashi, Taku
    Faye, Adam S.
    Lama, Sonie
    Charles, Lorna
    Cetin, Volkan
    Petersen, AnnKatrin
    Wu, Hsiuanlin
    Wang, Dong
    Jain, Anjali
    Sabino, Joao
    GASTROENTEROLOGY, 2024, 166 (05) : S805 - S806
  • [27] Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2TOUCHSTONE Study
    Sandborn, William J.
    Feagan, Brian G.
    Hanauer, Stephen
    Vermeire, Severine
    Ghosh, Subrata
    Liu, Wenzhong J.
    Petersen, AnnKatrin
    Charles, Lorna
    Huang, Vivian
    Usiskin, Keith
    Wolf, Douglas C.
    D'Haens, Geert
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (07): : 1120 - 1129
  • [28] Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis
    Julian Panes
    Anthony Otley
    Yuri Sanchez Gonzalez
    Kristina Fitzgerald
    Wen Zhou
    Dapo Ilo
    Triza Brion
    Muna J. Tahir
    Digestive Diseases and Sciences, 2023, 68 : 2318 - 2332
  • [29] Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis
    Panes, Julian
    Otley, Anthony
    Gonzalez, Yuri Sanchez
    Fitzgerald, Kristina
    Zhou, Wen
    Ilo, Dapo
    Brion, Triza
    Tahir, Muna J. J.
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (06) : 2318 - 2332
  • [30] Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
    Awni, Walid M.
    Eckert, Doerthe
    Sharma, Shringi
    Mostafa, Nael M.
    Noertersheuser, Peter A.
    Pradhan, Rajendra S.
    Robinson, Anne
    Sandborn, William
    Hanauer, Stephen B.
    Colombel, Jean-Frederic
    Thakkar, Roopal
    GASTROENTEROLOGY, 2013, 144 (05) : S229 - S229
12345